@prefix dc: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix hasPart: . @prefix chebi: . @prefix go: . @prefix pfh: . @prefix hasAgent: . @prefix atcc: . @prefix occursIn: . @prefix hasAnnotation: . @prefix mesh: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasPart: chebi:59826, sub:_2 . sub:_2 geneProductOf: hgnc:9445; a Protein: . sub:_3 hasAgent: sub:_4; a go:0042789 . sub:_4 geneProductOf: pfh:STAT5%20Family; a Protein: . sub:_5 occursIn: mesh:D001943, mesh:D042361, atcc:HTB-133.aspx, species:9606; hasAnnotation: sub:_6; rdf:object sub:_3; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:_6 dc:subject "TextLocation"; rdf:value "Results" . sub:assertion rdfs:label "composite(p(HGNC:PRL),a(CHEBIID:59826)) -> tscript(p(PFH:\"STAT5 Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 2000 hand curated statements drawn from 57 PubMeds."; dce:rights "Copyright (c) 2011-2012, Selventa. All Rights Reserved."; dce:title "BEL Framework Small Corpus Document"; dc:license "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License"; pav:authoredBy sub:_8; pav:version "1.6" . sub:_7 prov:value """The β-casein promoter, known to be induced by Stat5 when activated by prolactin via prolactin receptors and JAK2, was next used to test the function of the phosphorylated Stat5. T47D-YB cells were pretreated with either R5020 or ethanol vehicle for 48 h. Cells were then washed, transfected with a β-casein promoter-luciferase reporter, treated with either R5020 or prolactin, and harvested for luciferase assay 24 h after hormone treatment. We found that in T47D-YB breast cancer cells, prolactin alone has minimal to no significant effect on the β-casein luciferase promoter. However, after R5020 pretreatment, a 6–7-fold induction of the β-casein luciferase promoter was observed (Fig.7B). Thus R5020 sensitized these breast cancer cells to the transcriptional effects of prolactin mediated through Stat5."""; prov:wasQuotedFrom pubmed:9813040 . sub:_8 rdfs:comment "support@belframework.org"; rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:9813040; prov:wasDerivedFrom beldoc:, sub:_7 . } sub:pubinfo { this: dc:created "2014-07-03T14:29:30.808+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }